Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Psoriasis | 12 | 2021 | 1739 | 3.03 | Why? |
| Fasting | 3 | 2019 | 555 | 1.15 | Why? |
| Hidradenitis Suppurativa | 3 | 2018 | 309 | 1.03 | Why? |
| Jet Lag Syndrome | 1 | 2019 | 27 | 0.83 | Why? |
| Rosacea | 1 | 2021 | 57 | 0.82 | Why? |
| Pemphigoid, Bullous | 1 | 2021 | 89 | 0.80 | Why? |
| Skin Physiological Phenomena | 1 | 2019 | 27 | 0.78 | Why? |
| Hair Diseases | 1 | 2019 | 31 | 0.77 | Why? |
| Arthritis, Psoriatic | 3 | 2021 | 625 | 0.77 | Why? |
| Scalp Dermatoses | 1 | 2019 | 59 | 0.74 | Why? |
| Receptors, Calcitriol | 1 | 2019 | 102 | 0.74 | Why? |
| Acne Vulgaris | 2 | 2021 | 198 | 0.73 | Why? |
| Pemphigus | 1 | 2021 | 163 | 0.73 | Why? |
| Thalidomide | 1 | 2021 | 247 | 0.72 | Why? |
| Facial Dermatoses | 1 | 2021 | 222 | 0.68 | Why? |
| Adalimumab | 3 | 2021 | 389 | 0.67 | Why? |
| Skin Diseases | 5 | 2020 | 2509 | 0.66 | Why? |
| Biological Products | 3 | 2021 | 2331 | 0.66 | Why? |
| Periodontal Diseases | 1 | 2018 | 87 | 0.65 | Why? |
| Cholangitis | 1 | 2017 | 81 | 0.64 | Why? |
| Anti-Allergic Agents | 1 | 2018 | 167 | 0.64 | Why? |
| Omalizumab | 1 | 2018 | 158 | 0.63 | Why? |
| Dermatitis, Occupational | 1 | 2021 | 310 | 0.62 | Why? |
| Drug Eruptions | 2 | 2020 | 319 | 0.55 | Why? |
| Nitric Oxide | 2 | 2018 | 769 | 0.54 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 451 | 0.50 | Why? |
| Urticaria | 1 | 2018 | 472 | 0.47 | Why? |
| Abdominal Pain | 1 | 2017 | 858 | 0.45 | Why? |
| Phosphodiesterase 4 Inhibitors | 3 | 2021 | 112 | 0.44 | Why? |
| Vitamins | 1 | 2019 | 1208 | 0.40 | Why? |
| Skin | 2 | 2020 | 2096 | 0.40 | Why? |
| Disabled Persons | 2 | 2019 | 1152 | 0.38 | Why? |
| Needs Assessment | 1 | 2019 | 2352 | 0.37 | Why? |
| Molecular Targeted Therapy | 1 | 2018 | 1579 | 0.37 | Why? |
| Islam | 3 | 2019 | 545 | 0.36 | Why? |
| Italy | 17 | 2021 | 38444 | 0.34 | Why? |
| Chronic Disease | 2 | 2019 | 5139 | 0.34 | Why? |
| Ultraviolet Therapy | 2 | 2018 | 138 | 0.31 | Why? |
| Masks | 4 | 2021 | 8528 | 0.31 | Why? |
| Lung Diseases, Interstitial | 1 | 2017 | 1476 | 0.30 | Why? |
| Immunosuppressive Agents | 2 | 2021 | 6331 | 0.30 | Why? |
| Methotrexate | 2 | 2021 | 471 | 0.30 | Why? |
| State Medicine | 1 | 2019 | 2847 | 0.29 | Why? |
| Caregivers | 1 | 2019 | 3112 | 0.27 | Why? |
| Anti-Inflammatory Agents | 3 | 2020 | 6153 | 0.27 | Why? |
| Autoimmune Diseases | 1 | 2018 | 1996 | 0.27 | Why? |
| Vitamin D | 1 | 2019 | 2904 | 0.26 | Why? |
| Dermatitis, Atopic | 2 | 2021 | 714 | 0.23 | Why? |
| Saliva | 1 | 2018 | 4679 | 0.23 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 3832 | 0.21 | Why? |
| Pyoderma Gangrenosum | 2 | 2018 | 41 | 0.21 | Why? |
| Tetracyclines | 1 | 2020 | 82 | 0.20 | Why? |
| Bevacizumab | 1 | 2021 | 149 | 0.20 | Why? |
| Cost of Illness | 2 | 2021 | 1903 | 0.19 | Why? |
| Fumarates | 1 | 2019 | 38 | 0.19 | Why? |
| Hair Dyes | 1 | 2018 | 8 | 0.19 | Why? |
| Humans | 49 | 2021 | 930598 | 0.19 | Why? |
| Phenylenediamines | 1 | 2018 | 19 | 0.19 | Why? |
| Dermatitis, Irritant | 1 | 2020 | 99 | 0.19 | Why? |
| Phototherapy | 1 | 2020 | 138 | 0.18 | Why? |
| Sentinel Lymph Node | 1 | 2018 | 35 | 0.18 | Why? |
| Inflammation | 2 | 2018 | 13255 | 0.18 | Why? |
| Ceremonial Behavior | 1 | 2019 | 63 | 0.18 | Why? |
| Adult | 21 | 2021 | 244371 | 0.18 | Why? |
| Intraabdominal Infections | 1 | 2019 | 90 | 0.18 | Why? |
| Skin Pigmentation | 1 | 2018 | 98 | 0.18 | Why? |
| Histiocytosis | 1 | 2017 | 16 | 0.18 | Why? |
| Mucous Membrane | 1 | 2020 | 305 | 0.18 | Why? |
| Directive Counseling | 1 | 2018 | 77 | 0.17 | Why? |
| Breath Tests | 2 | 2018 | 338 | 0.17 | Why? |
| Evaluation Studies as Topic | 1 | 2019 | 391 | 0.17 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2018 | 66 | 0.17 | Why? |
| Janus Kinases | 1 | 2021 | 414 | 0.17 | Why? |
| Melanoma | 2 | 2019 | 1229 | 0.17 | Why? |
| Hereditary Autoinflammatory Diseases | 1 | 2018 | 72 | 0.17 | Why? |
| Middle Aged | 23 | 2021 | 270681 | 0.17 | Why? |
| Symptom Flare Up | 1 | 2021 | 432 | 0.17 | Why? |
| Dermatitis, Exfoliative | 1 | 2017 | 50 | 0.17 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 8811 | 0.17 | Why? |
| Self-Assessment | 1 | 2018 | 165 | 0.17 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.15 | Why? |
| Neoplasms | 3 | 2020 | 17251 | 0.15 | Why? |
| Disease Outbreaks | 2 | 2021 | 27595 | 0.15 | Why? |
| Dermatitis, Allergic Contact | 1 | 2018 | 185 | 0.15 | Why? |
| Male | 24 | 2021 | 367725 | 0.14 | Why? |
| Skin Neoplasms | 2 | 2019 | 1679 | 0.14 | Why? |
| Abscess | 1 | 2017 | 234 | 0.14 | Why? |
| Female | 21 | 2021 | 380317 | 0.13 | Why? |
| Cyclosporine | 1 | 2018 | 449 | 0.13 | Why? |
| Administration, Oral | 1 | 2021 | 2340 | 0.13 | Why? |
| Circadian Rhythm | 1 | 2019 | 607 | 0.13 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.13 | Why? |
| Bronchoalveolar Lavage | 1 | 2017 | 603 | 0.13 | Why? |
| Pneumococcal Vaccines | 1 | 2018 | 571 | 0.12 | Why? |
| Interferon-alpha | 1 | 2021 | 1442 | 0.12 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.12 | Why? |
| Aged | 16 | 2021 | 215776 | 0.12 | Why? |
| Exhalation | 1 | 2016 | 441 | 0.12 | Why? |
| Dendritic Cells | 1 | 2021 | 1330 | 0.12 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.11 | Why? |
| Inflammasomes | 1 | 2018 | 710 | 0.11 | Why? |
| Rats | 1 | 2019 | 2764 | 0.11 | Why? |
| Burns | 1 | 2017 | 466 | 0.11 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.11 | Why? |
| Hand Disinfection | 1 | 2020 | 1671 | 0.10 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.10 | Why? |
| Case-Control Studies | 4 | 2021 | 17671 | 0.10 | Why? |
| Antirheumatic Agents | 2 | 2021 | 3023 | 0.09 | Why? |
| Prognosis | 4 | 2020 | 32490 | 0.09 | Why? |
| Health Care Surveys | 1 | 2018 | 2942 | 0.09 | Why? |
| Quality of Life | 2 | 2021 | 9820 | 0.09 | Why? |
| Risk | 1 | 2020 | 5288 | 0.09 | Why? |
| Pilot Projects | 1 | 2019 | 5182 | 0.08 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2018 | 1380 | 0.08 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.08 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.08 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.07 | Why? |
| Remote Consultation | 1 | 2020 | 2396 | 0.07 | Why? |
| Health Promotion | 1 | 2019 | 2020 | 0.07 | Why? |
| Bacterial Infections | 1 | 2019 | 2229 | 0.07 | Why? |
| Research | 1 | 2018 | 2115 | 0.07 | Why? |
| Social Support | 1 | 2019 | 3183 | 0.07 | Why? |
| Artificial Intelligence | 1 | 2020 | 3543 | 0.07 | Why? |
| Dermatology | 1 | 2020 | 1999 | 0.07 | Why? |
| Referral and Consultation | 1 | 2021 | 4816 | 0.07 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.07 | Why? |
| Reference Values | 2 | 2018 | 795 | 0.07 | Why? |
| Young Adult | 9 | 2021 | 93724 | 0.07 | Why? |
| Surveys and Questionnaires | 3 | 2020 | 43792 | 0.06 | Why? |
| Severity of Illness Index | 4 | 2019 | 48226 | 0.06 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.06 | Why? |
| Liver | 1 | 2018 | 4007 | 0.06 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.06 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.06 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.06 | Why? |
| Liver Diseases | 1 | 2018 | 2698 | 0.06 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.06 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.06 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.06 | Why? |
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2021 | 65 | 0.06 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.06 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.06 | Why? |
| Toll-Like Receptor 9 | 1 | 2021 | 72 | 0.05 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.05 | Why? |
| Age Factors | 5 | 2021 | 21039 | 0.05 | Why? |
| Tumor Necrosis Factor-alpha | 2 | 2021 | 2483 | 0.05 | Why? |
| Oligonucleotides | 1 | 2021 | 137 | 0.05 | Why? |
| Immunity, Innate | 1 | 2018 | 6570 | 0.05 | Why? |
| Administration, Cutaneous | 1 | 2020 | 229 | 0.05 | Why? |
| American Cancer Society | 1 | 2018 | 2 | 0.05 | Why? |
| Aging | 1 | 2016 | 3581 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.05 | Why? |
| Mice | 1 | 2019 | 21357 | 0.05 | Why? |
| Cryopyrin-Associated Periodic Syndromes | 1 | 2018 | 20 | 0.05 | Why? |
| Sickness Impact Profile | 1 | 2018 | 56 | 0.05 | Why? |
| beta-Lactamase Inhibitors | 1 | 2019 | 104 | 0.04 | Why? |
| Pruritus | 1 | 2020 | 215 | 0.04 | Why? |
| Biomedical Research | 1 | 2019 | 5270 | 0.04 | Why? |
| Patch Tests | 1 | 2018 | 114 | 0.04 | Why? |
| Biopsy, Needle | 1 | 2018 | 303 | 0.04 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.04 | Why? |
| Toll-Like Receptor 7 | 1 | 2021 | 402 | 0.04 | Why? |
| Radiotherapy Dosage | 1 | 2018 | 428 | 0.04 | Why? |
| Infliximab | 1 | 2021 | 502 | 0.04 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.04 | Why? |
| Angiogenesis Inhibitors | 1 | 2021 | 395 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2019 | 10083 | 0.04 | Why? |
| beta-Lactams | 1 | 2019 | 210 | 0.04 | Why? |
| Quality-Adjusted Life Years | 1 | 2019 | 511 | 0.04 | Why? |
| Arthritis, Infectious | 1 | 2018 | 111 | 0.04 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.04 | Why? |
| Neoplasm Invasiveness | 1 | 2018 | 582 | 0.04 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.04 | Why? |
| Global Burden of Disease | 1 | 2019 | 531 | 0.04 | Why? |
| Survival Analysis | 2 | 2020 | 7592 | 0.04 | Why? |
| Hospitals, Special | 1 | 2020 | 523 | 0.04 | Why? |
| Confidence Intervals | 1 | 2018 | 744 | 0.04 | Why? |
| Body Temperature | 1 | 2021 | 875 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2018 | 1008 | 0.04 | Why? |
| Piperidines | 1 | 2021 | 795 | 0.03 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.03 | Why? |
| Drug Resistance, Microbial | 1 | 2019 | 419 | 0.03 | Why? |
| Awareness | 1 | 2019 | 529 | 0.03 | Why? |
| NF-kappa B | 1 | 2021 | 1301 | 0.03 | Why? |
| Pyrimidines | 1 | 2021 | 1557 | 0.03 | Why? |
| Animals | 2 | 2020 | 78931 | 0.03 | Why? |
| beta-Lactamases | 1 | 2019 | 759 | 0.03 | Why? |
| Program Development | 1 | 2019 | 1089 | 0.03 | Why? |
| Adjuvants, Immunologic | 1 | 2021 | 1709 | 0.03 | Why? |
| Neoplasm Staging | 1 | 2018 | 1999 | 0.03 | Why? |
| Protein Kinase Inhibitors | 1 | 2021 | 1585 | 0.03 | Why? |
| Sex Factors | 2 | 2018 | 11014 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2018 | 2275 | 0.03 | Why? |
| Telemedicine | 2 | 2020 | 25032 | 0.03 | Why? |
| Risk Assessment | 3 | 2020 | 25439 | 0.03 | Why? |
| Program Evaluation | 1 | 2019 | 1929 | 0.03 | Why? |
| Exanthema | 1 | 2020 | 1097 | 0.03 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2018 | 1165 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Drug Combinations | 1 | 2019 | 3852 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2021 | 4020 | 0.02 | Why? |
| Bacteria | 1 | 2019 | 1897 | 0.02 | Why? |
| Transcriptome | 1 | 2021 | 3466 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Computational Biology | 1 | 2021 | 4514 | 0.02 | Why? |
| Signal Transduction | 1 | 2021 | 7207 | 0.02 | Why? |
| Fever | 1 | 2021 | 7795 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.01 | Why? |
| United Kingdom | 1 | 2020 | 18046 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| Incidence | 1 | 2019 | 25622 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| Global Health | 1 | 2019 | 13911 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| China | 1 | 2021 | 50654 | 0.01 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.01 | Why? |
Damiani's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(224)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(154)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_